S1418 Pembrolizumab in Treating Patients with Triple-Negative Breast Cancer - Mercy Medical Center

S1418 Pembrolizumab in Treating Patients with Triple-Negative Breast Cancer

Posted on: January 30, 2020

This phase III trials studies how well pembrolizumab works in treating patients with triple negative breast cancer. Immunotherapy with monoclonial antibodies, such as pembrolizumab, may help the body’s immune system attack the cancer and may interfere with the ability of tumor cells to grow and spread. The eligibility includes being at least 18 years old and:

•Patients must have histologically confirmed estrogen receptor (ER)-, progesterone receptor (PR)- and HER2-negative (triple-negative, TNBC) or ER-, PR- weakly positive, and HER2- equivocal status and must not have received and not be planning to receive adjuvant anti-HER2 or endocrine therapies after completion of neoadjuvant chemotherapy

•Patients must not have metastatic disease

Patients must have a complete axillary lymph node dissection after neoadjuvant chemotherapy

•Patients may receive post-operative (adjuvant) chemotherapy for up to 24 weeks of duration (e.g. 8 cycles of capecitabine as in the CREATE-X trial) after completion of surgery at the discretion of the treating physician

This randomized phase III trial studies how well pembrolizumab works in treating patients with triple-negative breast cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

This randomized phase III trial studies how well pembrolizumab works in treating patients with triple-negative breast cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

Leave a Reply

Mercy Medical Center | 1320 Mercy Drive NW, Canton, OH 44708 | info@cantonmercy.org
Contact Us | Careers | Privacy Policy | Copyright © 2017 Mercy Medical Center